Highbridge Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Highbridge Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-5,605	Closed	-$609K	–	1786
2016 Q4	$609K	Buy	+5,605	New	+$668K	0.01%	699
2016 Q3	–	Sell	-25,900	Closed	-$3.69M	–	1756
2016 Q2	$3.69M	Buy	+25,900	New	+$3.78M	0.06%	319
2015 Q3	–	Sell	-2,871	Closed	-$693K	–	1886
2015 Q2	$693K	Buy	+2,871	New	+$765K	0.01%	848
2015 Q1	–	Sell	-37,218	Closed	-$5.81M	–	1635
2014 Q4	$5.81M	Buy	+37,218	New	+$6.87M	0.07%	283

Other funds holding ICPT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Highbridge Capital Management's ICPT Position: Q1 2017 in Review

Highbridge Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2017, closing a stake of 5,605 shares — an estimated $609K sold.

Highbridge Capital Management first reported a position in ICPT in Q4 2014 and held it in 4 quarters. The position peaked at $5.81M in Q4 2014. 150 funds tracked by Wall St. Rank hold ICPT as of Q1 2017.

Highbridge Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Highbridge Capital Management sold 5,605 Intercept Pharmaceuticals, Inc. shares in Q1 2017, an estimated $609K.
Highbridge Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and held it in 4 quarters.
Highbridge Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $5.81M in Q4 2014.
150 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2017.

Based on Highbridge Capital Management's 13F filing for Q1 2017, filed 15 May 2017.